Advanced Search:
Equity Index Forex Crypto Commodity

DXCM - DexCom

$136.14  -3.48 (-2.49%)

Updated: 03:09 May 5, 2024 EST

Next Hour's AI Forecast

99.07%

Avg. Accuracy (AI)

$126.64

Next Session's AI Forecast

94.86%

Avg. Accuracy (AI)

$136.12

Next Week's AI Forecast

83.33%

Trend's Accuracy (AI)

$135.19

DexCom's Position Within the Medical Devices Industry
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)
0 (Bottom)
100 (Top) Data Normalization
Rank (0-100)

DEXCOM - HISTORICAL DATA 6M

  • Last price

    $ 136.14

  • Daily change

    $ -3.48

  • Previous Close

    $ 139.62

  • Last Updated

    03:09 May 5, 2024 EST

CURRENT VOLATILITY

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.9 -0.41 0.15 0.3 0.04

CURRENT VOLATILITY RANK

Variation from the lowest to the highest value in a period.

Curr. Week Curr. Month Curr. Quarter Next Quarter Curr Year
0.9 1.72 1.58 1.59 1.86

STOCHASTIC METRIC

The STOCHASTIC METRIC shows when a financial asset has moved into an overbought or oversold position.

OVERSOLD
OVERBOUGHT
Curr. Week Next Week Curr. Month Curr. Quarter
100% 100% 36.05% 60.54%

MOVING AVERAGE METRIC

5 Sessions Change 5 Sessions 20 Sessions Change 20 Sessions 50 Sessions Change 50 Sessions 200 Sessions
129.06 -0.55% 129.77 -3.32% 134.22 10.67% 121.28

RSI METRIC

RS Hour RSI Hour RS Day RSI Day
0.7 44.75 0.68 41.18

DexCom Technical Analysis News

DexCom

6340 Sequence Drive
San Diego, CA 92121
United States
858 200 0200
https://www.dexcom.com

Sectors: Healthcare
Industry: Medical Devices
F. Time Employees: 9500
Description

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Corporate Governance

DexCom, Inc.’s ISS Governance QualityScore as of May 1, 2024 is 5. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 6; Compensation: 2.

DEXCOM'S HOLDERS RANK

List of holders with stock participation in DexCom.

Holder Rank Holder Shares Date Reported % Out Value